retatrutide glp-1 gip glucagon receptor agonist Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing Science Behind GLP 1 GIP

This local knowledge allows them to provide more relevant advice and support tailored to Orange County residents

Nausea was reported in a significant proportion of participants, particularly during the dose-escalation period (Jastreboff et al., 2023)

Prior reports have also cited cost to be a barrier to use for a large portion of patients, with monthly costs up to $1349 before insurance, rebates, or other discounts ( 2 , 12 )

However, phase I and II clinical trial results have shown that although retatrutide has promising results for weight loss, it may have a few side effects to consider

But in the case of research into Calocarb, the New Zealand government funded much of it

A critical point that Al Gore made in our recent podcast